Recently, Wuhan YZY Biopharma Co., Ltd completed a 200 million CNY Pre-C round of financing. This round of financing was completed by the joint investment of Wuhan Hi-Tech, Hubei Science Technology Investment and Optics Valley Financial Holding Group. Funds will be used for clinical research and development of product pipelines including dual antibodies and COVID-19 vaccine, and to accelerate product launch.

At present, YZY Biopharma has 5 clinical and multiple pre-clinical pipeline products under development, covering multiple disease fields such as oncology, ophthalmology, and COVID-19.

M701 is the first antibody drug targeting EpCAM/CD3 in the clinic. It can specifically bind to EpCAM-positive tumor cells, and at the same time bind to the T cell surface antigen CD3, recruit and activate T cells to kill tumor cells, and its main indications are EpCAM-positive tumors malignant ascites/pleural effusion. The clinical phase I of M701 has been completed, and the interim research results of phase I clinical trial have been published on the ESMO official website, showing good safety, tolerability and efficacy. The product is currently undergoing phase II clinical research.

Y2019 COVID-19 vaccine combines design research results of Wuhan Institute of Virology, Chinese Academy of Sciences and the advantages of YZY Biopharma recombinant protein industrialization platform, and has advantages in product quality control and large-scale production. Y2019 vaccine has good stability at room temperature and 4°C, and can be quickly produced in large-scale production. At present, the vaccine is being carried out in the phase I clinical study of the adult group and the elderly group by Hubei Center for Disease Control and Prevention. The preliminary results show that the vaccine is safe, and further phase II clinical studies will be carried out in near future.